Zevra Therapeutics submitted a Marketing Authorization Application to the European Medicines Agency for Arimoclomol, targeting Niemann-Pick Disease Type C.
4 reports, 2 independent
Updated Jul 24
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zevra Therapeutics submitted a Marketing Authorization Application to the European Medicines Agency for Arimoclomol, targeting Niemann-Pick Disease Type C.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
EMA
Japanese vocalist of the group DUSTCELL
Nothing else this week.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- GlobeNewswireZevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C CELEBRATION, Fla., July 28, 2025 (GL
- GlobeNewswireZevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference CELEBRATION, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Zevra Th